Seven Fleet Capital Management LP Buys 1,533 Shares of Madrigal Pharmaceuticals, Inc. $MDGL

Posted by Brenda Bartman on Aug 2nd, 2026

Seven Fleet Capital Management LP lifted its position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 82.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,393 shares of the biopharmaceutical company’s stock after buying an additional 1,533 shares during the quarter. Seven Fleet Capital Management LP’s holdings in Madrigal Pharmaceuticals were worth $1,776,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Flagship Harbor Advisors LLC purchased a new position in Madrigal Pharmaceuticals during the fourth quarter valued at approximately $29,000. Kemnay Advisory Services Inc. bought a new position in Madrigal Pharmaceuticals in the 4th quarter valued at $39,000. Quarry LP bought a new position in Madrigal Pharmaceuticals in the 3rd quarter valued at $39,000. Johnson Financial Group Inc. bought a new position in Madrigal Pharmaceuticals in the 3rd quarter valued at $50,000. Finally, Accent Capital Management LLC grew its position in shares of Madrigal Pharmaceuticals by 64.9% during the 4th quarter. Accent Capital Management LLC now owns 94 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 37 shares in the last quarter. 98.50% of the stock is currently owned by institutional investors.

Key Headlines Impacting Madrigal Pharmaceuticals

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

Positive Sentiment: Rezdiffra continues to drive strong revenue growth. Second-quarter revenue reached $364.25 million, up 71.2% year over year and above the $352.13 million analyst consensus, reflecting continued demand for the company’s MASH drug. Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates
Positive Sentiment: The quarterly loss was narrower than expected. Madrigal reported a loss of $1.99 per share, beating estimates ranging from $2.55 to $2.68 per share, although the loss was wider than the $1.90-per-share loss recorded a year earlier. Madrigal Reports Q2 Loss, Beats Revenue Estimates
Positive Sentiment: Analyst support remains favorable. Wells Fargo assigned Madrigal an Overweight rating, providing a positive signal for the company’s outlook. Madrigal Earns Overweight Rating from Wells Fargo
Neutral Sentiment: Madrigal’s earnings call and quarterly presentation highlighted Rezdiffra’s contribution to the business and the company’s ongoing development efforts, but investors are weighing the pace of the commercial launch against the stock’s elevated valuation. Madrigal Q2 2026 Earnings Call Transcript
Negative Sentiment: Shares fell despite the earnings beat. Investors appear concerned that Rezdiffra’s commercial growth is moderating, making the strong year-over-year revenue increase less compelling and raising expectations for evidence of sustained prescribing and sales momentum. MDGL Stock Down Despite Q2 Beat

Insider Buying and Selling

In related news, insider David Soergel sold 1,042 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $495.74, for a total transaction of $516,561.08. Following the transaction, the insider owned 10,033 shares of the company’s stock, valued at approximately $4,973,759.42. This trade represents a 9.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard S. Levy sold 5,682 shares of Madrigal Pharmaceuticals stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $515.44, for a total transaction of $2,928,730.08. Following the completion of the transaction, the director owned 22,015 shares in the company, valued at approximately $11,347,411.60. The trade was a 20.51% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 7,568 shares of company stock valued at $3,880,711. Company insiders own 17.60% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a report on Friday, July 17th. Citigroup reissued an “outperform” rating on shares of Madrigal Pharmaceuticals in a research note on Friday, July 17th. Evercore set a $649.00 target price on Madrigal Pharmaceuticals in a research report on Thursday, May 7th. HC Wainwright restated a “buy” rating on shares of Madrigal Pharmaceuticals in a research note on Friday. Finally, Canaccord Genuity Group upped their target price on Madrigal Pharmaceuticals from $578.00 to $587.00 and gave the stock a “buy” rating in a research note on Wednesday. Fourteen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Madrigal Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $688.20.

Read Our Latest Stock Analysis on Madrigal Pharmaceuticals

Madrigal Pharmaceuticals Stock Performance

NASDAQ:MDGL opened at $467.32 on Friday. The business has a 50 day moving average of $516.48 and a 200 day moving average of $499.05. The company has a market capitalization of $10.78 billion, a price-to-earnings ratio of -36.25 and a beta of -1.05. Madrigal Pharmaceuticals, Inc. has a 1-year low of $290.00 and a 1-year high of $615.00. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.50 and a quick ratio of 3.16.

Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.99) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.68) by $0.69. Madrigal Pharmaceuticals had a negative return on equity of 55.04% and a negative net margin of 25.32%.The business had revenue of $364.25 million during the quarter, compared to analyst estimates of $352.13 million. During the same quarter in the prior year, the firm earned ($1.90) earnings per share. Madrigal Pharmaceuticals’s revenue for the quarter was up 71.2% on a year-over-year basis. On average, sell-side analysts predict that Madrigal Pharmaceuticals, Inc. will post -7.47 earnings per share for the current fiscal year.

Madrigal Pharmaceuticals Profile

(Free Report)

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.